top of page

The Impact of Medical Cannabis Laws on Opioid Overdose Mortality Rates

The opioid crisis continues to escalate in the United States, largely fueled by the increasing prescription rates for chronic pain treatment. Amidst this disturbing trend, medical cannabis laws have emerged as a subject of interest. A time-series analysis conducted from 1999 to 2010 shows that states with medical cannabis laws experienced a 24.8% lower mean annual opioid overdose mortality rate compared to states without such laws. This article delves deeper into this association, examining the objective, methodology, and outcomes of the original study while discussing its implications and relevance.


The primary aim of the original study was to ascertain the relationship between the enactment of state medical cannabis laws and the rate of opioid analgesic overdose mortality.


The original study involved a comprehensive analysis of medical cannabis laws and state-level death certificate data across all 50 states. The variables included were the presence of state medical cannabis programs and age-adjusted opioid analgesic overdose death rates. The study employed regression models that considered state and year fixed effects, three different policies regarding opioid analgesics, and state-specific unemployment rates.

Key Findings

Three states—California, Oregon, and Washington—had enacted medical cannabis laws before 1999. Between 1999 and 2010, ten more states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) followed suit. Remarkably, states with medical cannabis laws showed a 24.8% lower mean annual opioid overdose mortality rate compared to states without these laws. This relationship generally strengthened over time, from year 1 to year 6 post-implementation, thereby suggesting a sustained impact of the medical cannabis laws on reducing opioid-related deaths.

Conclusion and Relevance

The study's results suggest that the enactment of medical cannabis laws could be a potent strategy in mitigating the opioid crisis. However, more research is needed to understand the interaction between medical cannabis laws and policies aimed at preventing opioid overdose.


With the increasing availability of medical cannabis as a treatment for chronic pain, there's an opportunity for a paradigm shift in the medical community's approach to pain management. The decreased rates of opioid overdose deaths in states with medical cannabis laws indicate that offering an alternative to opioids for pain treatment can have a profound societal impact. While medical cannabis laws may not be the sole answer to the opioid crisis, they could be a part of a multifaceted solution, alongside better prescription monitoring and improved access to substance abuse treatment.


The study concludes that further investigation is required. Among the questions that need to be addressed are whether medical cannabis serves as a "gateway" or "stepping stone" to other substances and how it interacts with opioids pharmacologically.

Final Thoughts

As the opioid crisis continues to strain healthcare resources and claim lives, the potential benefits of medical cannabis laws cannot be ignored. Policymakers and healthcare providers should consider the adoption and refinement of medical cannabis laws as a strategy to combat the growing opioid epidemic.

The information used in this article was adapted from a time-series analysis conducted from 1999 to 2010, using the Wide-ranging Online Data for Epidemiologic Research interface to multiple cause-of-death data from the Centers for Disease Control and Prevention.

  1. Gaskin, Darrell J., and Richard P. "The Economic Costs of Pain in the United States." J Pain, vol. 13, no. 8, 2012, pp. 715–724. PubMed.

  2. Daubresse, M., et al. "Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000–2010." Med Care, vol. 51, no. 10, 2013, pp. 870–878. PubMed Central.

  3. Centers for Disease Control and Prevention. "Vital Signs: Overdoses of Prescription Opioid Pain Relievers—United States, 1999–2008." MMWR Morb Mortal Wkly Rep, vol. 60, no. 43, 2011, pp. 1487–1492.

  4. Jones, Christopher M., et al. "Pharmaceutical Overdose Deaths, United States, 2010." JAMA, vol. 309, no. 7, 2013, pp. 657–659.

  5. National Center for Injury Prevention and Control Division of Unintentional Injury Prevention. Policy Impact: Prescription Painkiller Overdoses. November 2011,

  6. National Conference of State Legislatures. State Medical Marijuana Laws. 7 July 2014,


bottom of page